Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94781Review ArticleReview Current state of the problem of chronic venous diseases of the lower extremitiesKudykinM. Nmady5@yandex.ruVolga Federal Medical Research Center17072017197-1525628122021Copyright © 2017, Consilium Medicum2017The paper discusses current data on epidemiology, pathogenesis, and clinical manifestations of chronic venous disease of the lower extremities. A comparative analysis of various phlebotrophic drugs for the treatment of manifestations of chronic venous disease and chronic venous insufficiency, discusses the benefits of micronized purified flavonoid fraction for the treatment of all classes of chronic venous diseases.chronic venous diseaseschronic venous insufficiencyvaricose veinspost-thrombotic syndromediosminmicronized purified flavonoid fractionphlebotrophic therapyFlebavenхронические заболевания венхроническая венозная недостаточностьварикозная болезньпосттромботический синдромдиосминмикронизированная очищенная флавоноидная фракцияфлеботропная терапияФлебавен[Шлякова А.А., Корнева К.Г., Кудыкин М.Н., Перетягин П.В. Особенности микроциркуляции нижних конечностей у пациентов с сахарным диабетом 2 типа в сочетании с хронической венозной недостаточностью. Терапевт. 2014; 1: 15-8.][Bergan J.J, Schmid-Schonbein G.W, Coleridge-Smith P.D. Chronic venous disease. N Engl J Med 2006; 355 (3): 488-96.][Nicolaides A, Kakkos S, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol 2014; 33 (2): 87-208.][Allegra C, Antignani P-L, Bergan J.J et al. The “С” of CEAP: Suggested definitions and refinements: An international Union of Phlebology conference of experts. J Vasc Surg 2003; 37 (1): 129-31.][Rabe E, Guex J-J, Puskas A et al. The VCP Coordinators Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol 2012; 31 (2): 105-15.][Eklof B, Perrin M, Delis K.T et al. Up - date terminology of chronic venous disorders: The VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg 2009; 49: 498-501.][Богачев В.Ю. Современная фармакотерапия хронической венозной недостаточности нижних конечностей. Фармацевтический вестн. 2006; 10 (2): 54-9.][Ruckley C.V, Fowkes F.G.R, Bradbury A.W. Venous Disease. Epidemiology, Management and Delivery of Care. Springer 1999; 278.][Jawien A, Grzela T, Ochwat A. Prevalence of chronic venous insufficiency in men and women in Poland: multicentre cross - sectional study in 40095 patients. Phlebology 2003; 81: 110-22.][Langer R.D, Ho E, Deneberg J.O et al. Relation - ship between symptoms and venous disease. Arch Int Med 2005; 165: 1420-4.][Labropoulos N, Stansby G. Venous and Lymphatic Diseases. Taylor & Francis 2006; 559.][Schmid-Schonbein G.W, Granger D.N. Molecular Basis for Microcirculatory Disorders. Springer 2003; 640.][Nicolaides A.N, Allegra C, Bergan J et al. Management of Chronic Venous Disorders of the Lower Limbs Guidelines According to Scientific Evidence. Int Angiol 2008; 27: 1-59.][Ramelet A-A, Perrin M, Kern P, Bounameaux H. Phlebology, 5-th ed. Elsevier Masson 2008: 565.][Davies A.H. Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2015. pii: S1078-5884(15)00699-1. DOI: 10.1016/j.ejvs.2015.09.024][Varicose Veins in the Legs: The Diagnosis and Management of Varicose Veins. National Clinical Guideline Centre (UK). London: National Institute for Health and Care Excellence (UK), 2013.][Российские клинические рекомендации по диагностике и лечению хронических заболеваний вен. Флебология. 2013; 2: 6-47.][Katsenis K. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency. Curr Vasc Pharmacol 2005; 3 (1): 1-9.][Jantet G. RELIEF Study Group. Chronic Venous Insufficiency: Worlwide Results of the RELIEF Study. Angiology 2002; 53: 245-6.][Rabe E, Agus G.B, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol 2015; 34 (5): 428-36.][Pitsch F. Assessment of treatment efficacy on venous symptoms: the example of Detralex. Phlebo - lymphology 2008; 15: 137-42.][Belczak S.Q, Sincos I.R, Campos W et al. Veno - active drugs for chronic venous disease: A randomized, double - blind, placebo - controlled parallel - design trial. Phlebology 2014; 29 (7): 454-60. DOI: 10.1177/0268355513489550][Colerige-Smith P, Lok C, Ramelet A.A. Venous leg ulcer: meta - analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005; 30: 198-208.][Чеснокова Н.Н., Кононова С.В., Запорожская Л.И., Кудыкин М.Н. Исследование сегмента регионального рынка лекарственных препаратов для лечения и профилактики варикозной болезни нижних конечностей. Мед. альманах. 2015; 4 (39): 205-9.][Colerige-Smith P. From Skin Disorders to Venous Leg Ulcers: Pathophysiology and Efficacy of Daflon 500 mg in Ulcer Healing. Angiology 2003; 54 (Suppl. 1): 45-50.][Handbook of venous disorders. 7-nd ed. Guidelines Am Venous Forum 2017; 557.]